SR
MRNA icon

Syntax Research’s Moderna MRNA Stock Holding History

Syntax Research’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$2.76K – 179
2025
Q2 		$2.76K Hold
100
– – ﹤0.01% 164
2025
Q1 		$2.83K Hold
100
– – ﹤0.01% 168
2024
Q4 		$4.16K Hold
100
– – ﹤0.01% 171
2024
Q3 		$6.68K Buy
+100
New +$9.18K ﹤0.01% 160
2024
Q1 		– Sell
-50
Closed -$4.97K – 178
2023
Q4 		$4.97K Buy
+50
New +$4.21K ﹤0.01% 161

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Syntax Research's MRNA Position: Q3 2025 in Review

Syntax Research sold out of Moderna (MRNA) in Q3 2025, closing a stake of 100 shares — an estimated $2.76K sold.

Syntax Research first reported a position in MRNA in Q4 2023 and held it in 5 quarters. The position peaked at $6.68K in Q3 2024. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Syntax Research reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Syntax Research sold 100 Moderna shares in Q3 2025, an estimated $2.76K.
  • Syntax Research first reported a position in Moderna in Q4 2023 and held it in 5 quarters.
  • Syntax Research's Moderna position peaked at $6.68K in Q3 2024.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Syntax Research's 13F filing for Q3 2025, filed 4 Nov 2025.